 |
|
|
| |
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
J Eron,1 D Margolis,2 J Gonzalez-Garcia,3 H-J Stellbrink,4 Y Yazdanpanah,5 D Podzamczer,6
T Lutz,7 JB Angel,8 GJ Richmond,9 B Clotet,10 F Gutierrez,11 L Sloan,12 KC Sutton,2 D Dorey,13 KY Smith,2 PE Williams,14 WR Spreen2
1University of North Carolina at Chapel Hill, Division of Infectious Diseases, Chapel Hill, NC, USA; 2ViiV Healthcare, Research Triangle Park, NC, USA; 3Hospital Universitario La Paz/IdiPAZ, Madrid, Spain; 4ICHHamburg, Hamburg, Germany; 5Hopital Bichat Claude Bernard, Paris, France; 6Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain; 7Infektiologikum, Frankfurt, Germany; 8The Ottawa Hospital, Ottawa, ON, Canada; 9Broward General Medical Center, Fort Lauderdale, FL, USA; 10Hospital Germans Trias i Pujol, UAB, UVICUCC, Badalona, Spain; 11Hospital General de Elche & Universidad Miguel Hernandez, Alicante, Spain; 12North Texas Infectious Disease Consultants, Dallas, TX, USA; 13GlaxoSmithKline, Mississauga, ON, Canada; 14Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
